Genelux (NASDAQ:GNLX – Get Free Report) and Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.
Earnings and Valuation
This table compares Genelux and Cyclerion Therapeutics’ gross revenue, earnings per share and valuation.
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Genelux | $170,000.00 | 371.79 | -$28.30 million | ($0.97) | -1.90 |
Cyclerion Therapeutics | $1.62 million | 3.85 | -$5.26 million | N/A | N/A |
Cyclerion Therapeutics has higher revenue and earnings than Genelux.
Analyst Ratings
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Genelux | 0 | 0 | 4 | 0 | 3.00 |
Cyclerion Therapeutics | 0 | 0 | 0 | 0 | N/A |
Genelux presently has a consensus price target of $32.33, suggesting a potential upside of 1,657.25%. Given Genelux’s higher possible upside, research analysts plainly believe Genelux is more favorable than Cyclerion Therapeutics.
Institutional and Insider Ownership
37.3% of Genelux shares are held by institutional investors. Comparatively, 75.6% of Cyclerion Therapeutics shares are held by institutional investors. 9.3% of Genelux shares are held by insiders. Comparatively, 13.1% of Cyclerion Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
Genelux has a beta of -1.57, meaning that its stock price is 257% less volatile than the S&P 500. Comparatively, Cyclerion Therapeutics has a beta of 1.85, meaning that its stock price is 85% more volatile than the S&P 500.
Profitability
This table compares Genelux and Cyclerion Therapeutics’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Genelux | N/A | -125.58% | -86.03% |
Cyclerion Therapeutics | N/A | -77.93% | -61.09% |
Summary
Cyclerion Therapeutics beats Genelux on 7 of the 10 factors compared between the two stocks.
About Genelux
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to out-license for cardiovascular diseases; and Praliciguat, a systemic sGC stimulator that is licensed to Akebia Therapeutics, Inc. for the treatment of rare kidney disease. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Receive News & Ratings for Genelux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genelux and related companies with MarketBeat.com's FREE daily email newsletter.